Nvidia and Genentech Partner on AI Infrastructure for Drug Discovery at BIO2026
In brief
- Nvidia VP Kimberly Powell and Genentech CEO Ashley Magargee presented their AI partnership at BIO2026 in San Diego, June 22–25
- Multi-year partnership combines Genentech's biological datasets with Nvidia's computing infrastructure to accelerate drug discovery
- Nvidia launched BioNeMo agent toolkit on June 23, 2026, integrating generative AI into life sciences workflows
The partnership: data meets infrastructure
Nvidia and Genentech formalized their multi-year partnership on November 21, 2023, built on a straightforward premise: Genentech's decades of accumulated biological and clinical data, combined with Nvidia's processing power, creates a foundation for AI-driven drug development. Genentech operates as part of the Roche Group and maintains an extensive library of biological and clinical data from decades of drug development work.
Nvidia brings its BioNeMo platform and DGX Cloud infrastructure to process and model that data at scale. The combination lets researchers apply machine learning and generative AI to problems that would otherwise take years to solve manually.
BioNeMo toolkit launch
During the convention, Nvidia launched the BioNeMo agent toolkit on June 23, 2026. The toolkit is designed to integrate generative AI and agent-based systems into life sciences research workflows, making it easier for biotech teams to deploy AI without building infrastructure from scratch.
The broader industry is moving in this direction. Eli Lilly, Microsoft, and Insilico Medicine all participated in AI-focused sessions at the convention, signaling that AI-driven drug discovery is no longer a fringe bet—it's becoming central to how the industry operates.
The Nvidia-Genentech case makes one thing clear: the companies with the best data and the fastest compute will move fastest in this space.
